GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer
on February 23 2021 9:00 PM
SYDNEY & LAGUNA HILLS, Calif. (BUSINESS WIRE) #breastcancerawareness GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx
TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.
DCISionRT
® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test, developed by PreludeDx, assesses a woman’s 10-year risk of recurrence of DCIS or development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patients who will benefi